GlioCure

📍 Angers, France🗓 Founded 2016👥 5 employees💰 Last funded Mar 2024
Biotechnology Research🌐 gliocure.com
Website LinkedIn
GlioCure, a spin-off company of Angers and McGill Montreal universities, aims to treat glioblastoma that causes 200,000 deaths worldwide each year. To overcome this challenge, GlioCure is hyper-specialized and develops glioblastoma-specific drugs. GlioCure is currently focusing on the development of GC01, an anti-glioblastoma peptide discovered by Joël Eyer, Director of Research from INSERM, and covered by two patent families for which GlioCure owns worldwide exclusive rights. GlioCures team has the experience and the know-how to ensure the successful completion of GC01’s development plan: Louis-Marie is a biotech entrepreneur with 15 years of experience in the field of innovative therapies and rare diseases; Claire, specialist of the neuronal cytoskeleton, has sound knowledge of preclinical experimental techniques; Its Scientific & Medical Advisory Board is composed of leading international experts in research and treatment of glioblastoma.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in GlioCure?
GlioCure has 1 investors on record on gritt.io and 1 late-stage investors.
When did GlioCure last raise funding?
The most recent investment in GlioCure recorded on gritt.io was in March 2024.
When was GlioCure founded?
GlioCure was founded in 2016.
What industry is GlioCure in?
GlioCure operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is GlioCure based?
GlioCure is headquartered in Angers, France.